TY - JOUR
T1 - Validation of the simplified Animal Naming Test as primary screening tool for the diagnosis of covert hepatic encephalopathy
AU - Labenz, Christian
AU - Beul, Larissa
AU - Toenges, Gerrit
AU - Schattenberg, Jörn M.
AU - Nagel, Michael
AU - Sprinzl, Martin F.
AU - Nguyen-Tat, Marc
AU - Zimmermann, Tim
AU - Huber, Yvonne
AU - Marquardt, Jens U.
AU - Galle, Peter R.
AU - Wörns, Marcus Alexander
N1 - Publisher Copyright:
© 2018 European Federation of Internal Medicine
PY - 2019/2
Y1 - 2019/2
N2 - Background: Diagnosis of covert hepatic encephalopathy (CHE) is time consuming in clinical practice. Recently, a new diagnostic tool - the simplified Animal Naming Test (S-ANT1) - was presented with promising results in an Italian cohort. The aim of the present study was to validate S-ANT1 in a cohort of cirrhotic patients from a German tertiary referral centre. Methods: 143 cirrhotic patients and 37 healthy controls were enrolled. Hepatic encephalopathy (HE) grade 1 (HE1) was clinically diagnosed according to the West-Haven Criteria. Critical flicker frequency and Psychometric Hepatic Encephalopathy Score were used to detect minimal HE (MHE). All participants were additionally examined by S-ANT1. Results: 58 (40.6%) patients presented with CHE (40 MHE, 18 HE1). S-ANT1 was lowest in patients with HE1, followed by patients with MHE, patients without CHE, and healthy controls, respectively (each p < 0.05). Naming <20 animals discriminated best between patients with and without CHE in ROC analysis (with Youden's index). With a cut-off value of ≥23 mentioned animal names further testing for CHE could be avoided in 38.5% of patients with a negative predictive value of 84%. Conclusions: S-ANT1 may become an important first screening tool for the assessment of CHE in clinical practice.
AB - Background: Diagnosis of covert hepatic encephalopathy (CHE) is time consuming in clinical practice. Recently, a new diagnostic tool - the simplified Animal Naming Test (S-ANT1) - was presented with promising results in an Italian cohort. The aim of the present study was to validate S-ANT1 in a cohort of cirrhotic patients from a German tertiary referral centre. Methods: 143 cirrhotic patients and 37 healthy controls were enrolled. Hepatic encephalopathy (HE) grade 1 (HE1) was clinically diagnosed according to the West-Haven Criteria. Critical flicker frequency and Psychometric Hepatic Encephalopathy Score were used to detect minimal HE (MHE). All participants were additionally examined by S-ANT1. Results: 58 (40.6%) patients presented with CHE (40 MHE, 18 HE1). S-ANT1 was lowest in patients with HE1, followed by patients with MHE, patients without CHE, and healthy controls, respectively (each p < 0.05). Naming <20 animals discriminated best between patients with and without CHE in ROC analysis (with Youden's index). With a cut-off value of ≥23 mentioned animal names further testing for CHE could be avoided in 38.5% of patients with a negative predictive value of 84%. Conclusions: S-ANT1 may become an important first screening tool for the assessment of CHE in clinical practice.
UR - http://www.scopus.com/inward/record.url?scp=85051659165&partnerID=8YFLogxK
U2 - 10.1016/j.ejim.2018.08.008
DO - 10.1016/j.ejim.2018.08.008
M3 - Journal articles
C2 - 30131209
AN - SCOPUS:85051659165
SN - 0953-6205
VL - 60
SP - 96
EP - 100
JO - European Journal of Internal Medicine
JF - European Journal of Internal Medicine
ER -